首页 | 本学科首页   官方微博 | 高级检索  
     


Desymmetrization of pibrentasvir for efficient prodrug synthesis
Authors:Eric A. Voight  Stephen N. Greszler  John Hartung  Jianguo Ji  Russell C. Klix  John T. Randolph  Bhadra H. Shelat  Jan E. Waters  David A. DeGoey
Affiliation:Drug Discovery Science & Technology, AbbVie, Inc., 1 North Waukegan Road, North Chicago Illinois 60064-1802 USA.; Process Research and Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago Illinois 60064-1802 USA
Abstract:A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated via a one-pot di-Boc/mono-de-Boc selective N-Boc protection and formaldehyde adduct formation sequence, both enabled by crystallization-induced selectivity. The first step represents the only known application of the Horeau principle of statistical amplification for C2-symmetric polyheterocycle regioselective functionalization. The resulting versatile intermediate is employed in the high-yielding preparation of several pibrentasvir prodrug candidates.

Horeau principle statistical amplification and solubility-driven selectivities allow C2-desymmetrization of pibrentasvir without typically required internal functionalization or steric proximity effects.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号